Incidence and spectrum of typical complications associated with immunosuppressant use in rheumatic disease: A nationwide retrospective study
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70054 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Soyoung Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Rheumatic Diseases, Immunosuppressive Agents, Opportunistic Infections. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Korea Health Industry Development Institute, Ministry of Health, Ministry of Health, British Columbia.
Abstract (Originalsprache)
Aim
To estimate the incidence and characteristics of typical complications associated with immunosuppressant therapy across various types of rheumatic disease (RD).
Methods
We conducted a retrospective analysis using Korean claims data, including patients who were first diagnosed with rheumatic disease (rheumatoid arthritis, spondyloarthrosis, lupus erythematosus, vasculitis, sclerosis, Sjögren's syndrome, and polymyalgia rheumatica) and initiated immunosuppressant therapy between 2015 and 2018. We focused on several typical complications, including infections, cancer, cardiovascular complications, bone marrow suppression, gastrointestinal complications, diabetes, interstitial lung disease, demyelinating disease, acute kidney injury, and hepatotoxicity.
Results
Among 464 753 patients prescribed immunosuppressants, 59 548 initiated treatment following their RD diagnosis. The most prevalent complications included opportunistic infections (60.6 events per 1000 person‐years), serious infections (41.1), hypertension (31.5), diabetes (18.3), and cancer (14.1). Most complications peaked in the first month after treatment initiation. While the risk of serious infections and cancer increased with age, the incidence of opportunistic infections did not significantly vary. Furthermore, risk of serious infection or cancer did not significantly differ among RD types.
Conclusions
This investigation elucidated the incidence and spectrum of typical complications associated with immunosuppressants among patients with RD, using a vast real‐world dataset to highlight key safety concerns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.
- College of Pharmacy, Chungbuk National University, Cheongju, Republic of Korea.
- College of Pharmacy, Yeungnam University, Gyeongsangbuk-do, Republic of Korea.
ORCID-Profile: Young-Mi Ah, Ju-Yeun Lee
Förderung
- Korea Health Industry Development Institute
- Ministry of Health
- Ministry of Health, British Columbia
Zitieren
APA
Park, S., Lee, A. Y., Jeong, J., Heo, K. N., Han, J. M., Ah, Y. M., & Lee, J. Y. (2025). Incidence and spectrum of typical complications associated with immunosuppressant use in rheumatic disease: A nationwide retrospective study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70054
Vancouver
Park S, Lee AY, Jeong J, Heo KN, Han JM, Ah YM, et al. Incidence and spectrum of typical complications associated with immunosuppressant use in rheumatic disease: A nationwide retrospective study. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70054
BibTeX
@article{Park2025,
author = {Park, Soyoung and Lee, Ah Young and Jeong, Jonghyun and Heo, Kyu-Nam and Han, Ji Min and Ah, Young-Mi and Lee, Ju-Yeun},
title = {Incidence and spectrum of typical complications associated with immunosuppressant use in rheumatic disease: A nationwide retrospective study},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70054}
}
EUVIMED